Seung Edward, Mordes John P, Greiner Dale L, Rossini Aldo A
Diabetes Division, University of Massachusetts Medical School, Two Biotech, 373 Plantation Street, Suite 218, Worcester, MA 01605, USA.
Curr Diab Rep. 2003 Aug;3(4):329-35. doi: 10.1007/s11892-003-0026-9.
Type 1 diabetes is an autoimmune disorder characterized by selective destruction of pancreatic b cells and absolute insulin deficiency. Even when treated well, control is imperfect and complications inevitable. Advances in immunosuppressive drugs and preparation of donor islets have recently made curative islet transplantation a reality for type 1 diabetes. Unfortunately, short-term side effects and long-term health risks of lifelong systemic immunosuppression compromise the otherwise extraordinary benefits that accrue from a successful graft. Our current goal is to obviate the need for immunosuppression and achieve islet graft tolerance. New protocols based on costimulation blockade have brought us close to that goal, inducing states of both peripheral and central transplantation tolerance. These have overcome both allograft rejection and recurrent autoimmunity, but potentially detrimental effects of environmental agents on tolerance are not yet fully understood. Studies of the underlying mechanisms have provided new insights into the nature of both tolerance and autoimmunity.
1型糖尿病是一种自身免疫性疾病,其特征是胰腺β细胞被选择性破坏以及绝对的胰岛素缺乏。即使治疗得当,血糖控制也并不完美,并发症不可避免。免疫抑制药物和供体胰岛制备方面的进展最近使治愈性胰岛移植成为1型糖尿病的现实疗法。不幸的是,终身全身免疫抑制的短期副作用和长期健康风险损害了成功移植所带来的显著益处。我们目前的目标是消除免疫抑制的需求并实现胰岛移植耐受。基于共刺激阻断的新方案已使我们接近这一目标,诱导了外周和中枢移植耐受状态。这些方案克服了同种异体移植排斥和复发性自身免疫,但环境因素对耐受的潜在有害影响尚未完全了解。对潜在机制的研究为耐受和自身免疫的本质提供了新的见解。